Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase EARLY_PHASE1 1Phase 1/2 1

Status

Withdrawn 2Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 6Breast 4Thoracic 3Gynecologic 3Genitourinary 3Gastrointestinal 2Head & Neck 1

Conditions

Breast Neoplasms 14Endometrial Neoplasms 11Ovarian Neoplasms 10Pancreatic Neoplasms 9Stomach Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Uterine Cervical Neoplasms 6Prostatic Neoplasms 6Colorectal Neoplasms 6Urinary Bladder Neoplasms 5Lung Neoplasms 5Esophageal Neoplasms 5Neoplasms 4Breast Neoplasms, Male 4Thyroid Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Sarcoma 3Salivary Gland Neoplasms 3Rectal Neoplasms 3Neoplasm Metastasis 3Gallbladder Neoplasms 3Colonic Neoplasms 3Carcinoma, Renal Cell 3Carcinoma, Ovarian Epithelial 3Carcinoma, Hepatocellular 3Vulvar Neoplasms 2Vipoma 2Vaginal Neoplasms 2Uterine Neoplasms 2Urethral Neoplasms 2

Interventions

Filgrastim 15Carboplatin 10Ifosfamide 9Doxorubicin 9Cyclophosphamide 9Peripheral Blood Stem Cell Transplantation 7pembrolizumab 6Radiotherapy 6Gemcitabine 6Temozolomide 5Etoposide 5Cisplatin 5Paclitaxel 4Docetaxel 4Amifostine 4aldesleukin 3aflibercept 3Trastuzumab 3Specimen Handling 3Radiosurgery 3Psychiatric Rehabilitation 3Magnetic Resonance Spectroscopy 3Biopsy 3tislelizumab 2sodium thiosulfate 2selinexor 2pazopanib 2palbociclib 2etoposide phosphate 2eribulin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Sarcoma × Trastuzumab × Gynecologic × Clear all
NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

OHSU Knight Cancer Institute

Phase EARLY_PHASE1 Withdrawn
BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

NCT04464967 2021-05-12

Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers

NKGen Biotech, Inc.

Phase 1/2 Withdrawn
BreastGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Recurrence, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT00433407 2012-10-04

T-Cell Response in Patients Receiving Trastuzumab and/or Chemotherapy for HER2-Positive Solid Tumors

Jonsson Comprehensive Cancer Center

Phase NA Completed
12 enrolled
BreastGenitourinaryGynecologicSarcomaThoracic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Breast Neoplasms, Male, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡